StreetInsider.com News Articles

Form 8-K HERON THERAPEUTICS, INC. For: Aug 13

Fri, 14 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260814/26931547.html

Form 8-K HERON THERAPEUTICS, INC. For: Aug 13

Fri, 14 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260814/26931547.html

H.C. Wainwright Downgrades Heron Therapeutics (HRTX) to Neutral

Tue, 11 Aug 2026 06:03:26 -0400

H.C. Wainwright analyst Brandon Folkes downgraded Heron Therapeutics (NASDAQ: HRTX) from Buy to Neutral.

For an analyst ratings summary and ratings history on Heron Therapeutics click here. For more ratings news on Heron Therapeutics click here.

Shares of Heron Therapeutics closed at $0.34 yesterday.

Form 4 HERON THERAPEUTICS, INC. For: Aug 06 Filed by: Hensley Mark Earl

Mon, 10 Aug 2026 10:19:00 -0400

si-local-file:///var/storage/secattach/20260810/26895812.html

Form 4 HERON THERAPEUTICS, INC. For: Aug 06 Filed by: Hensley Mark Earl

Mon, 10 Aug 2026 10:19:00 -0400

si-local-file:///var/storage/secattach/20260810/26895812.html

Heron Therapeutics (HRTX) Misses Q2 EPS by 2c

Mon, 10 Aug 2026 08:07:44 -0400

Heron Therapeutics (NASDAQ: HRTX) reported Q2 EPS of ($0.03), $0.02 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $37.67 million versus the consensus estimate of $42.13 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

Form 10-Q HERON THERAPEUTICS, INC. For: Jun 30

Mon, 10 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260810/26894725.html

Form 10-Q HERON THERAPEUTICS, INC. For: Jun 30

Mon, 10 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260810/26894725.html

Heron Therapeutics Announces Second Quarter 2026 Financial Results

Mon, 10 Aug 2026 08:00:00 -0400

– Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF^® net revenue grew 35% and APONVIE^® net revenue grew 74% year-over-year

– Amended credit facility with Hercules Capital: financial covenants reset through 2027, and outstanding principal to be reduced by a total potential reduction of $17.5 million — $13.5 million at execution and a potential further reduction of $4 million scheduled on or before September 15, 2026

– Withdrew full-year 2026 financial guidance

CARY, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX)

Heron Therapeutics Announces Second Quarter 2026 Financial Results

Mon, 10 Aug 2026 08:00:00 -0400

– Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF^® net revenue grew 35% and APONVIE^® net revenue grew 74% year-over-year

– Withdrew full-year 2026 financial guidance

CARY, N.C., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX)

Form 8-K HERON THERAPEUTICS, INC. For: Aug 10

Mon, 10 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260810/26894687.html

Form 8-K HERON THERAPEUTICS, INC. For: Aug 10

Mon, 10 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260810/26894687.html

Form 4 HERON THERAPEUTICS, INC. For: Jul 31 Filed by: Hensley Mark Earl

Mon, 03 Aug 2026 11:21:00 -0400

si-local-file:///var/storage/secattach/20260803/26855885.html

Form 4 HERON THERAPEUTICS, INC. For: Jul 31 Filed by: Hensley Mark Earl

Mon, 03 Aug 2026 11:21:00 -0400

si-local-file:///var/storage/secattach/20260803/26855885.html

Form 4 HERON THERAPEUTICS, INC. For: Jul 30 Filed by: Forbes William P

Mon, 03 Aug 2026 11:00:00 -0400

si-local-file:///var/storage/secattach/20260803/26855739.html

Form 4 HERON THERAPEUTICS, INC. For: Jul 30 Filed by: Forbes William P

Mon, 03 Aug 2026 11:00:00 -0400

si-local-file:///var/storage/secattach/20260803/26855739.html

Form 4 HERON THERAPEUTICS, INC. For: Jul 30 Filed by: Duarte Ira

Mon, 03 Aug 2026 09:50:00 -0400

si-local-file:///var/storage/secattach/20260803/26855315.html

Form 4 HERON THERAPEUTICS, INC. For: Jul 30 Filed by: Duarte Ira

Mon, 03 Aug 2026 09:50:00 -0400

si-local-file:///var/storage/secattach/20260803/26855315.html

Form 4 HERON THERAPEUTICS, INC. For: Jul 30 Filed by: Collard Craig A

Mon, 03 Aug 2026 09:32:00 -0400

si-local-file:///var/storage/secattach/20260803/26855224.html

Form 4 HERON THERAPEUTICS, INC. For: Jul 30 Filed by: Collard Craig A

Mon, 03 Aug 2026 09:32:00 -0400

si-local-file:///var/storage/secattach/20260803/26855224.html

Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026

Mon, 27 Jul 2026 08:30:00 -0400

CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m. ET to report second quarter financial results and discuss recent business highlights.

The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start

Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026

Mon, 27 Jul 2026 08:30:00 -0400

Form 4 HERON THERAPEUTICS, INC. For: Jul 19 Filed by: Collard Craig A

Mon, 20 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260720/26789971.html

Form 4 HERON THERAPEUTICS, INC. For: Jul 19 Filed by: Collard Craig A

Mon, 20 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260720/26789971.html

Form 4 HERON THERAPEUTICS, INC. For: Jul 19 Filed by: Forbes William P

Mon, 20 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260720/26789810.html